AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Leveraging mTOR Inhibition to Restore Keratinocyte Homeostasis Across Rare Monogenic Skin Disorders

11:30 am - Thursday 5th November 2026

Identifying shared pathological mechanisms across monogenic keratin disorders through translational research and patient-derived models
Evaluating mTOR inhibition as a strategy to restore cellular homeostasis and improve disease outcomes across genetically distinct indications
Leveraging cross-indication biology to create scalable development pathways in ultra-rare dermatology populations

Karen McGuire

Chief Executive Officer

BioMendix